UBS AM
XERS icon

UBS AM’s Xeris Biopharma Holdings XERS Stock Holding History

UBS AM’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.45M Buy
687,632
+19,558
+3% +$125K ﹤0.01% 1562
2026
Q1 		$3.87M Buy
668,074
+16,629
+3% +$110K ﹤0.01% 1692
2025
Q4 		$5.11M Buy
651,445
+467,986
+255% +$3.68M ﹤0.01% 1449
2025
Q3 		$1.49M Buy
183,459
+145,840
+388% +$969K ﹤0.01% 1867
2025
Q2 		$176K Buy
+37,619
New +$172K ﹤0.01% 2570

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS AM's XERS Position: Q2 2026 in Review

UBS AM increased its Xeris Biopharma Holdings (XERS) stake by 2.9% in Q2 2026, buying an estimated $125K and bringing the position to 687,632 shares worth $5.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1562.

UBS AM first reported a position in XERS in Q2 2025 and has held it in 5 quarters since. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • UBS AM held 687,632 shares of Xeris Biopharma Holdings worth $5.45M as of Q2 2026.
  • UBS AM bought 19,558 Xeris Biopharma Holdings shares in Q2 2026, an estimated $125K.
  • Xeris Biopharma Holdings made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1562 holding.
  • UBS AM first reported a position in Xeris Biopharma Holdings in Q2 2025 and has held it in 5 quarters since.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.